West Pharma (WST) Tops Q4 EPS by 10c, Revenues Beat; Initiates FY20 EPS/Revenue Mid-Point Guidance Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. META
5. MU
6. NVDA
7. BLZE
8. IBM
9. PRIM
10. ACN

Go back to West Pharma (WST) Tops Q4 EPS by 10c, Revenues Beat; Initiates FY20 EPS/Revenue Mid-Point Guidance Above Consensus

West Announces Fourth-Quarter and Full-Year 2019 Results

February 13, 2020 6:00 AM EST

EXTON, Pa., Feb. 13, 2020 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the fourth-quarter and full-year 2019 and introduced full-year 2020 financial guidance.

Fourth-Quarter and Full-Year 2019 Summary (comparisons to prior-year period)

Fourth-quarter 2019 net sales of $470.6 million grew 11.4%; organic sales growth was 12.7%; sales from a recent acquisition contributed an additional 30 basis points of growth; currency... More